Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate

The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's ALDX ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL).
PVRL is a rare ocular lymphoid malignancy consisting of a subset of primary central system lymphoma (PCNSL) and the most common type of intraocular lymphoma.
ADX-2191 is designed to inhibit dihydrofolate reductase, an enzyme involved in cellular replication and activation.
Methotrexate is the most commonly used intravitreal medication for the treatment of PVRL.
Price Action: ALDX shares are up 7.18% at $9.85 during the premarket session on the last check Tuesday.